Study of the immunogenicity and protective properties of recombinant influenza vaccine

Sedova E.S.

Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya of the Ministry of Health of the Russian Federation

Stepanova L.A.

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation

Lysenko A.A.

Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya of the Ministry of Health of the Russian Federation

Shcherbinin D.N.

Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya of the Ministry of Health of the Russian Federation

Verkhovskaya L.V.

Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya of the Ministry of Health of the Russian Federation

Tsybalova L.M.

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation

Shmarov M.M.

Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya of the Ministry of Health of the Russian Federation;
LLC «NTfarma»

Study of the immunogenicity and protective properties of recombinant influenza vaccine

Authors:

Sedova E.S., Stepanova L.A., Lysenko A.A., Shcherbinin D.N., Verkhovskaya L.V., Tsybalova L.M., Shmarov M.M.

More about the authors

Journal: Molecular Genetics, Microbiology and Virology. 2020;38(3): 136‑144

DOI: 10.17116/molgen202038031136

Downloaded: 211

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Sedova ES, Stepanova LA, Lysenko AA, Shcherbinin DN, Verkhovskaya LV, Tsybalova LM, Shmarov MM. Study of the immunogenicity and protective properties of recombinant influenza vaccine. Molecular Genetics, Microbiology and Virology. 2020;38(3):136‑144. (In Russ.)
https://doi.org/10.17116/molgen202038031136

Close metadata

THE AIM

A preclinical study of the immunogenicity and protective properties of the influenza trivalent vaccine AdeVac-Flu^TM in laboratory mice BALB/c strain.

MATERIAL AND METHODS

The vaccine AdeVac-Flu^TM is a mixture of recombinant human adenovirus 5 serotype encoding the hemagglutinin genes of influenza virus vaccine strains: A/California/07/2009 (H1N1), A/Perth/16/2009(H3N2), B/Brisbane/60/2008, as well as the molecular adjuvant Immunomax. As a reference drug, was used the live influenza virus vaccine Ultravak, produced by the FSUE SPA «Microgen». Balb/c mice were immunized once with AdeVac-Flu^TM intranasally and 28 days after immunization were infected with a lethal dose of influenza viruses A H1N1, H3N2 and influenza virus B. The level of virus accumulation in the lungs of infected mice was evaluated at 3 and 6 days after infection by titration the lung homogenates in MDCK cells. Evaluation of the humoral immune response to influenza viruses was performed by ELISA, HIA and VNA.

RESULTS

It was shown that the influenza vaccine AdeVac-Flu^TM is more immunogenic than the reference drug. Protection quality against homologous strains of influenza viruses via AdeVac-Flu^TM are either slightly lower or comparable to the reference drug. At the same time, it was shown that AdeVac-Flu^TM, as well as a live influenza virus vaccine, protects mice from a heterologous strain of the influenza virus, despite the fact that mice immunized with AdeVac-Flu^TM showed virus excretion from the lungs and a slight decrease in body weight (less than 10%).

CONCLUSIONS

AdeVac-Flu^TM vaccine based on recombinant human adenoviruses 5 serotype encoding the hemagglutinin genes of influenza viruses A/California/07/2009(H1N1), A/Perth/16/2009(H3N2), B/Brisbane/60/2008, possesses immunogenicity and protective properties in relation to both homologous and heterologous (within the subtype) strains of the influenza virus.

Keywords:

AdeVac-FluTM candidate flu vaccine

immunogenicity

protection

influenza A and B viruses

Authors:

Sedova E.S.

Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya of the Ministry of Health of the Russian Federation

Stepanova L.A.

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation

Lysenko A.A.

Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya of the Ministry of Health of the Russian Federation

Shcherbinin D.N.

Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya of the Ministry of Health of the Russian Federation

Verkhovskaya L.V.

Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya of the Ministry of Health of the Russian Federation

Tsybalova L.M.

Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation

Shmarov M.M.

Federal Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya of the Ministry of Health of the Russian Federation;
LLC «NTfarma»

Received:

27.09.2019

Accepted:

20.10.2019

List of references:

Paules C, Subbarao K. Influenza. Lancet. 2017;390:697-708. https://doi.org/10.1016/S0140-6736(17)30129-0
Zhang Y, Xu C, Zhang H, Liu GD, Xue C, Cao Y. Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus. Viruses. 2019;11(5):E405. https://doi.org/10.3390/v11050405
Sedova ES, Shcherbinin DN, Migunov AI, Smirnov YuA, Logunov DYu, Shmarov MM, et al. Recombinant influenza vaccines. Acta Naturae. 2012;4(4):17-27. (In Russ.).
Tompkins SM, Lin Y, Leser GP, Kramer KA, Haas DL, Howerth EW, et al. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology. 2007;362:139-150. https://doi.org/10.1016/j.virol.2006.12.005
Ertl HC. Viral vectors as vaccine carriers. Curr Opin Virol. 2016;21:1-8. https://doi.org/10.1016/j.coviro.2016.06.001
Hoelscher MA, Singh N, Garg S, Jayashankar L, Veguilla V, Pandey A, et al. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. Infect Dis. 2008;197(8):1185-1188. https://doi.org/10.1086/529522
Melidou A, Gioula G, Exindari M, Chatzidimitriou D, Diza-Mataftsi E. Influenza A(H5N1): an overview of the current situation. Eurosurveillance. 2009;14(20). https://doi.org/10.2807/ese.14.20.19216-en
Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One. 2008;3(12):e3942. https://doi.org/10.1371/journal.pone.0003942
Shmarov MM, Sedova ES, Verkhovskaya LV, Rudneva IA, Bogacheva EA, Barykova YA, et al. Induction of a Protective Heterosubtypic Immune Response Against the Influenza Virus by using Recombinant Adenoviral Vectors Expressing Hemagglutinin of the Influenza H5 Virus. Acta Naturae. 2010;2(1):111-118. (In Russ.).
Ataullakhanov RI, Pichugin AV, Shishkova NM, Masternak TB, Malkina EYu, Ulyanova LI, et al. Cell mechanisms of the immunomodulating action produced by drug «Immunomax». Immunologiya. 2005;26(2):111-120. (In Russ.).
Bagaev AV, Pichugin AV, Lebedeva ES, Lysenko AA, Shmarov MM, Logunov DY, et al. Regulation of the target protein (transgene) expression in the adenovirus vector using agonists of toll-like receptor. Acta Naturae. 2014;6(4):27-39. (In Russ.).
Bagaev AV, Pichugin AV, Lebedeva ES, Lysenko AA, Shmarov MM, Logunov DYu, et al. Influence of TLR-agonists on expression by antigen-presenting cells of the target protein antigen encoded in adenoviral vector. Immunologiya. 2015;36(4):188-195. (In Russ.).
Guidelines MU 3.3.2.1758—03 «Methods for determining the quality indicators of immunobiological drugs for the prevention and diagnosis of influenza». M. 2003. (In Russ.).
Methodical recommendations «Detection of antibodies to influenza A(H5N1) in the sera of humans and animals under natural infection and vaccination process in the reaction of microneutralization». M. 2009. (In Russ.).
Stepanova LA, Sergeeva MV, Shuklina MA, Shaldzhyan AA, Potapchuk MV, Korotkov AV, et al. A Fusion Protein Based on the Second Subunit of Hemagglutinin of Influenza A/H2N2 Viruses Provides Cross Immunity. Acta Naturae. 2016;8:116-26. (In Russ.).
Tutykhina IL, Sedova ES, Gribova IY, Ivanova TI, Vasilev LA, Rutovskaya MV. Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Res. 2013;97:318-328. https://doi.org/10.1016/j.antiviral.2012.12.021

Close metadata